Investigational drug · Phase 2
TPX-100
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Osteoarthritis (OA) of the Knee.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "TPX-100"
First trial start
2025
May 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TPX-100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Osteoarthritis (OA) of the Knee
Approved drugs for the same conditions: Osteoarthritis
Largest trials
Live from ClinicalTrials.gov: studies naming "TPX-100" as an intervention, largest first.
- 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the KneePivotal-lookingActive, not recruiting
OrthoTrophix, IncIndustry
NCT06865079 · 270 participants (planned) · Start May 9, 2025 · Primary completion Mar 25, 2027
Drug: TPX-100 200mg, Once weekly for 4 weeks · For: Osteoarthritis (OA) of the Knee
Sites: Scottsdale, Arizona; Tucson, Arizona; Carrolton, California · 33 sites in all
- A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both KneesPivotal-lookingCompleted
OrthoTrophix, IncIndustry
NCT01925261 · 120 participants (planned) · Start Jan 2014 · Primary completion Sep 2016
Drug: TPX-100 50mg; TPX-100 100mg and 3 more · For: Knee Osteoarthritis
Sites: Seattle, Washington
OrthoTrophix, IncIndustry
NCT02837900 · 14 participants · Start Aug 2016 · Primary completion Aug 2017
Drug: TPX-100 200 mg 4 times weekly for 4 weeks; TPX-100 200 mg 4 times weekly for 4 weeks · For: Knee Osteoarthritis
Newest research
PubMed records naming it or its code names, newest first.
- Emerging therapies for knee osteoarthritis.
Courties A, Winkler T, Conaghan PG, et al. · Nat Rev Rheumatol 2026
- Advances and Challenges in the Pursuit of Disease-Modifying Osteoarthritis Drugs: A Review of 2010-2024 Clinical Trials.
Brandt MD, Malone JB, Kean TJ · Biomedicines 2025
- Study TPX-100-5: intra-articular TPX-100 significantly delays pathological bone shape change and stabilizes cartilage in moderate to severe bilateral knee OA.
McGuire D, Bowes M, Brett A, et al. · Arthritis Res Ther 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.